Lundbeck launches Northera in USA

2 September 2014

Danish CNS specialist Lundbeck (LUND: CO) said today that Northera (droxidopa) capsules for oral use are now available through its US subsidiary for health care providers to prescribe in the USA.

Northera, developed by US firm Chelsea Therapeutics, is a norepinephrine prodrug that was approved by the US Food and Drug Administration earlier this year (The Pharma Letter February 19), and is now available across the USA through a specialty pharmacy. Lundbeck subsequently acquired Chelsea and Northera for around $658 million (TPL May 8).

Northera is only approved for the USA, where it is cleared for the treatment of orthostatic dizziness, lightheadedness or the "feeling that you are about to black out" in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK